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Abstract 24 
The contribution of ribosome heterogeneity and ribosome-associated proteins to the 25 
molecular control of proteomes in health and disease remains enigmatic. We demonstrate 26 
that Survival Motor Neuron (SMN) protein, loss of which causes the neuromuscular disease 27 
spinal muscular atrophy (SMA), binds to ribosomes and that this interaction is tissue-28 
dependent. SMN-primed ribosomes are preferentially positioned within the first five codons 29 
of a set of mRNAs which are enriched for translational enhancer sequences in the 5’UTR 30 
and rare codons at the beginning of their coding sequence. These SMN-specific mRNAs are 31 
associated with neurogenesis, lipid metabolism, ubiquitination, chromatin regulation and 32 
translation. Loss of SMN induces ribosome depletion, especially at the beginning of the 33 
coding sequence of SMN-specific mRNAs, leading to impairment of proteins involved in 34 
motor neuron function and stability, including acetylcholinesterase. Thus, SMN plays a 35 
crucial role in the regulation of ribosome fluxes along mRNAs which encode proteins 36 
relevant to SMA pathogenesis. 37 




Translation is the most energy consuming process in cells (1, 2) and represents a 40 
core mechanism coordinating multiple post-transcriptional processes. Hence, it is not 41 
surprising that several mRNAs are largely controlled at the translational, rather than 42 
transcriptional, level (3–5). Indeed, loss of post-transcriptional and translational control has 43 
been linked to cancer (6, 7), autism (8) and neurodegenerative disease (9–11), highlighting 44 
the critical contribution of translation to a broad spectrum of disease pathogenesis.  45 
Ribosomes have been placed in the spotlight as putative direct influencers of 46 
translation by acting as mRNA regulatory elements, or “filters” (12, 13). Recent findings also 47 
suggest that ribosome composition is not fixed and uniform, but rather is heterogeneous and 48 
can be modulated at the level of ribosomal protein composition (14–16), rRNA variants (17, 49 
18), and/or by ribosome-associated proteins (RAPs) (12, 19), which exert a direct role on 50 
mRNA selection (15) and function (19, 20). Although this represents an exciting potential 51 
mechanism for ribosome-based control of gene expression, at present it remains unclear 52 
whether direct or indirect defects in ribosome heterogeneity can contribute to disease 53 
pathogenesis.  54 
Depletion of Survival Motor Neuron (SMN) protein, following homozygous deletion or 55 
mutations in SMN1, causes spinal muscular atrophy (SMA) (21, 22). The human genome 56 
contains a second SMN gene (SMN2), almost identical to SMN1. Aberrant splicing of SMN2 57 
transcripts mostly results in a truncated and unstable protein. The remaining 10-20% of 58 
SMN2-derived mRNAs are translated into a full-length, stable SMN protein, rescuing the 59 
lethality of SMN1 loss in humans. SMA is primarily characterized by loss of lower motor 60 
neurons, leading to muscle atrophy and wasting. However, the molecular mechanisms 61 
leading to motor neuron death in SMA remain complex and unresolved (22–26). Although 62 
classically known to play a role in the biogenesis of ribonucleoparticles (RNPs) (27), SMN is 63 
also a strong candidate to be directly implicated in the control of translation: it is thought to 64 
associate with polysomes in cell cultures (11, 28), as well as rat and mouse spinal cords (11, 65 
29) and mouse brain (11). Moreover, SMN influences translation in vitro (11, 28, 30) and in 66 
vivo (11). Hence, it is possible that, in addition to its canonical roles (27), SMN protein 67 
functions as a ribosome modulator leading to early and local dysfunction of translation when 68 
levels of SMN are decreased. In line with this hypothesis, genome-wide defects occurring in 69 
mRNA recruitment onto polysomes have previously been observed in SMA (11), but the 70 
mechanism(s) linking SMN to these defects have yet to be elucidated.  71 
Here, we present evidence suggesting that SMN is a ribosome-associated protein 72 






SMN binds ribosomes in vitro and in vivo, with tissue specificity 77 
Guided by previous evidence suggesting an association of SMN with polysomes (11, 78 
28–30), we hypothesized that SMN may play an as yet uncharacterized role in regulating 79 
translation by acting as a ribosome-associated protein. To detail the interaction between 80 
SMN and ribosomes, we characterized the binding of recombinant SMN to purified SMN-free 81 
ribosomes obtained from cells which do not express the full length SMN (11). Using two 82 
complementary approaches (Fig. 1a) we found that SMN strongly binds ribosomes in vitro 83 
(Fig. 1b and c, Supplementary Table 1, Extended data Fig. 1a and b). Next, we 84 
performed subcellular fractionation coupled to high salt wash (31) (Fig. 1d) in mouse 85 
tissues. Before and after salt washes, SMN remained tightly associated with ribosomes in 86 
brain (Fig. 1e) and spinal cord (Extended data Fig. 1c). To monitor if the interaction of SMN 87 
with ribosomes/polysomes is mRNA dependent, we treated the ribosome/polysome pellet 88 
with RNase I and observed that SMN still sedimented with ribosomes/polysomes, suggesting 89 
that this association is mRNA-independent (Fig. 1f, Extended data Fig. 1d and e).  90 
Secondly, we co-immunoprecipitated SMN with ribosomal proteins and translation 91 
factors from purified polysomes, and found that SMN is associated with ribosomal proteins 92 
through protein-protein interactions and with the Poly(A) binding protein mainly via mRNA-93 
dependent interactions (Fig. 1g). Next, to understand whether SMN is preferentially 94 
associated to the large or small subunit of the ribosome, we induced the dissociation of the 95 
ribosomal subunits and found that SMN primarily co-sediments with the 60S subunit 96 
(Extended data Fig. 1f and g). 97 
Thirdly, to rule out the possibility that the observed interaction of SMN with ribosomes 98 
and polysomes derived from Gemin-granules (32, 33), we compared the co-sedimentation 99 
profile of SMN, Gemin- and RNA-granules after sucrose gradient fractionation of cell lysates. 100 
We found that SMN co-sediments independently from HuR, a marker of mRNA-granules, 101 
and from Gemin5, a marker of Gemin-granules, which has also been proposed to bind 102 
ribosomes (31) (Extended data Fig. 2a). These findings suggest that, in addition to being 103 
part of Gemin-granules, SMN is a bona fide ribosome-associated protein.  104 
Since SMN expression levels are known to be tissue-dependent (34), we next 105 
wanted to establish whether SMN displays distinctive ribosome binding ability in a tissue-106 
specific manner. To test this hypothesis, we established the relative co-sedimentation of 107 
SMN with ribonucleoparticles (RNPs), ribosomal subunits, ribosomes and polysomes in 108 
spinal cord, brain, kidney, liver and heart from wild-type mice (Fig. 2a and b and Extended 109 
data Fig. 2b-d). We observed a tissue-dependent association of SMN with the translation 110 
machinery (Fig. 2c). Interestingly, this variability was proportional with the overall abundance 111 
of SMN, as SMN levels negatively correlated with RNP association (r=-0.83 and positively 112 
4 
 
correlated with 60S, 80S and polysome association (r = 0.89, 0.99 and r=0.95 respectively) 113 
(Fig. 2d). This confirmed that the association of SMN with ribosomes and polysomes is 114 
tissue-specific and dependent on SMN concentration in vivo, similar to what we observed in 115 
vitro (Fig. 1b and c). This finding suggests that a subset of ribosomes are associated with 116 
SMN in a concentration and tissue-dependent manner in vivo. We termed these SMN-117 
associated ribosomes “SMN-primed ribosomes”. 118 
 119 
SMN positively regulates translation and is associated with actively translating ribosomes 120 
It has previously been proposed that SMN may act as a repressor of cap-dependent 121 
translation in vitro (28), but this result is not in complete agreement with recent findings, 122 
including in vivo studies where SMN loss leads to translation defects (11, 30, 35). Therefore, 123 
we wanted to establish whether SMN might positively regulate cap-independent translation 124 
and be associated with stalled or actively translating ribosomes. To test this, we took 125 
advantage of an in vitro transcription translation assay using different concentrations of 126 
recombinant SMN and a reporter gene whose translation is controlled by a viral translational 127 
enhancer element, in particular an IRES. We observed that higher concentrations of SMN 128 
led to higher production of reporter protein (Fig. 2e), suggesting that SMN is a positive 129 
regulator of translation in vitro.  130 
Next, we investigated the association of SMN to active ribosomes in cellulo using the 131 
RiboLace method (36), which facilitates the specific isolation of actively translating 132 
ribosomes. We confirmed that SMN is associated with active ribosomes and that this 133 
association is lost when translation is inhibited by puromycin, a translation inhibitor that 134 
releases active ribosomes from mRNAs (Fig. 2f). These findings show that SMN positively 135 
regulates translation by binding to actively translating ribosomes.  136 
 137 
SMN-primed ribosomes are positioned within the first five codons of a specific subset of 138 
mRNAs 139 
To establish whether SMN-primed ribosomes control a specific subset of mRNAs and 140 
where SMN-primed ribosomes are preferentially positioned along transcripts, we isolated 141 
SMN-primed ribosomes by immunoprecipitation and performed ribosome profiling in wild-142 
type mouse brains (Fig. 3a). SMN co-immunoprecipitated with RPL26 (Extended data Fig. 143 
3a), further demonstrating that SMN binds to ribosomes by RNA-independent interactions. 144 
By comparing RNA fragments protected by SMN-primed ribosomes to both control IgG and 145 
classical ribosome profiling performed on the same tissue (see Materials and Methods), we 146 
identified a set of 5587 transcripts, corresponding to 2842 genes (Supplementary Table 2). 147 
The vast majority of these transcripts (52%) were protein-coding genes (Extended data Fig. 148 
3b). SMN-primed ribosome protected fragments (RPFs) map prevalently to the coding 149 
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sequence (CDS), similar to control ribosome profiling (RiboSeq) data and distinct from RNA-150 
Seq of polysomal RNA (Fig. 3b).  151 
Next, we analyzed in detail the P-site position of SMN-primed RPFs near the start 152 
and stop codon of transcripts associated with SMN-primed ribosomes. Compared to 153 
classical ribosome profiling from control mouse brain, we observed a significant 154 
accumulation of signal within the first five codons of the CDS (Fig. 3c). Two distinct 155 
populations of RPFs with different lengths contributed to this effect: shorter fragments (24-26 156 
nucleotides) peaking on the fifth codon (Fig. 3d, upper panel), and longer fragments (32-34 157 
nucleotides) peaking on the first codon (Fig. 3d, lower panel). These two populations are 158 
shared among the selected transcripts (Extended data Fig. 3c) and may be associated with 159 
different ribosome conformations (37). We further confirmed that SMN-primed ribosomes 160 
preferentially occupy the beginning of the CDS by determining for each transcript the ratio 161 
between P-sites on the first 5 codons (initiation region) and the whole CDS (Fig. 3e). Since 162 
the P-site signal was lower and increasingly out of frame after the 5th codon (Extended data 163 
Fig. 3d), we considered the set of 874 protein coding transcripts (corresponding to 619 164 
genes) displaying a signal within the first codons as bona fide SMN-specific transcripts for 165 
further analysis. Representative coverage profiles of SMN-specific transcripts are shown in 166 
Extended data Fig. 3e.  167 
Expression analysis of cell types within compartments of the nervous system 168 
revealed the highest enrichment for motor neurons, followed by sensory neurons, astrocytes 169 
and oligodendrocytes (Extended data Fig. 3f). Gene Ontology analysis further highlighted 170 
the significant association of neuron-specific functions with mRNAs enriched in SMN-primed 171 
ribosomes (Extended data Fig. 3g). 172 
Finally, we charted known interactions between proteins coded by SMN-specific 173 
transcripts. Structural analysis of the network revealed the presence of seven communities, 174 
(Fig. 3f). Each community is characterized by a distinct functional identity (Extended data 175 
Fig. 3h). Ordered by decreasing gene number, the communities are related to: 176 
Axon/Cytoskeleton, Synapse/Vesicle, Ribosome/Translation, Chromatin/Histones, Fatty 177 
Acids, Ubiquitination, Rho GTPase cycle (Fig. 3f and Extended data Fig. 3h). These 178 
communities resemble several roles linked to SMN and themes that are known to be 179 
defective in SMA (11, 38, 47, 39–46). 180 
 181 
Transcripts bound by SMN-primed ribosomes display defects in ribosome recruitment at the 182 
beginning of the CDS during early stages of SMA 183 
To establish whether loss of SMN interaction with ribosomes gives rise to 184 
translational defects in SMA at early stages of disease (11), we first ruled out the possibility 185 
that translational changes are caused by pathways controlling translation, in particular the 186 
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PERK (Unfolded Protein Response) and mTORC1 pathways. (Extended data Fig. 4a and 187 
4B).  188 
Next, we analyzed the positioning of active ribosomes in SMA mouse brains and 189 
age-matched controls using the Active-RiboSeq method based on RiboLace (36) (Fig. 4a 190 
and Extended data Fig. 4c). Notably, the majority of genes with significantly altered 191 
translation (76%) were characterized by a decreased ribosome occupancy in SMA (Fig. 4b), 192 
in agreement with previously reported translation defects (11). As with SMN-specific 193 
transcripts, the 835 genes with defects in active translation were strongly enriched for both 194 
brain and spinal cord compartments, particularly motor neurons (Extended data Fig. 4d). 195 
Importantly, transcripts bound by SMN-primed ribosomes and with defects in active 196 
translation in SMA match transcripts previously associated with SMA and other motorneuron 197 
diseases such as ALS (Fig. 4c). 198 
Prompted by this finding, we further verified that SMN-specific transcripts display 199 
significantly decreased signal from Active-RiboSeq in SMA, with respect to SMN-unspecific 200 
transcripts (P: 1.3e-32, Fig. 4d), and that the loss of signal is located preferentially at the 201 
beginning of their CDS, (Fig. 4e, P: 2.1e-17). 202 
These results suggest that loss of SMN induces defects in ribosome occupancy 203 
within the first 5 codons of mRNAs bound by SMN-primed ribosomes, and that SMN is 204 
required during early stages of translation, when the nascent chain is short and not yet deep 205 
inside the exit tunnel of the ribosome.  206 
 207 
Translationally defective transcripts in SMA display deficient use of rare codons in the CDS 208 
and enrichment in translational enhancer sequences in the 5’UTR 209 
The association of SMN-primed ribosomes with the first five codons of a subset of 210 
mRNAs (Fig. 3c-f) involved in SMA and ALS (Fig. 4c) and defectively translated in SMA 211 
(Fig. 4d and e), suggests a ribosome-based mechanism underlying the pathophysiology and 212 
cell-type specificity of these diseases. Exploring in more detail the molecular and functional 213 
features of these mRNAs, we found that they largely encode proteins either localized to the 214 
nucleus or mitochondria, including both transmembrane and secreted proteins (Extended 215 
data Fig. 5a). These transcripts also display longer CDSs and shorter UTRs (Extended 216 
data Fig. 5b). Consistently with the reported propensity of SMN to bind RNA sequences rich 217 
in G and A (48, 49), GA-rich consensus motifs were found as enriched in both the 5’ and 218 
3’UTRs (Extended data Fig. 5c). The 5’ UTRs of SMN-specific transcripts are also enriched 219 
for sequences previously associated (50) with a translation regulatory function, that we 220 
termed translational enhancer sequences (Extended data Fig. 5d), in line with our in vitro 221 
results (Fig. 2e). Consistently, transcripts with translational enhancer sequences in their 5’ 222 
UTRs are more apt to show translational defects in SMA (Fig. 5a), especially SMN-specific 223 
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mRNAs (Fig. 5b). These results suggest that mRNAs bearing translational enhancer 224 
sequences in their 5’UTR might be more susceptible to translational defects upon SMN loss.  225 
By analyzing the composition of the CDS of SMN-specific mRNAs, we found that the 226 
first five codons are enriched for rare arginine codons (Extended data Fig. 5e). 227 
Furthermore, mRNAs with translational defects at the early stages of SMA are also enriched 228 
in rare codons (Fig. 5c), primarily encoding leucine and arginine amino-acids (Fig. 5d). 229 
Strikingly, arginine was the most frequent amino-acid within the first 5 codons in SMN-230 
specific transcripts with significant translational defects in SMA (Fig. 5e). 231 
These results suggest that mRNAs with rare codons at the beginning of the CDS are 232 
more prone to translational defects upon SMN loss than those with frequent codons. To 233 
confirm this, we used a luciferase assay and compared two reporters with either frequent or 234 
rare codons encoding for alanines at the 5’ of the luciferase CDS. We tested the translation 235 
efficiency of these reporters in motor neuron-like cells with low SMN expression levels 236 
(Extended data Fig. 5f), that recapitulate an in cellulo model of SMA. Using this assay, we 237 
confirmed that rare codons are more translationally sensitive to SMN depletion than frequent 238 
codons (Fig. 5f). 239 
Taken together these analyses suggest that mRNAs with decreased ribosome 240 
occupancy in SMA and enriched in SMN-primed ribosomes are characterized by the 241 
combination of translational enhancer sequences in the 5’UTR and by rare codons, 242 
especially arginines, at the beginning of the CDS (Fig. 5g). 243 
A luciferase reporter assay confirmed that the presence of the “arginine-rich” motif 244 
associated with SMN-specific transcripts induces a translational repression in cells 245 
expressing low levels of SMN (Fig. 5h and Extended data Fig. 5g). Similarly, a reporter 246 
gene under the control of the c-Myc translational enhancer sequence (Extended data Fig. 247 
5h) was less efficiently translated when cells expressed low levels of SMN (Fig. 5i). This 248 
decrease was still present by treating cells with rapamycin (an inhibitor of cap-dependent 249 
translation), confirming a positive role of SMN in cap-independent translation (Extended 250 
data Fig. 5h). A reporter containing both the “arginine-rich” motif and translational enhancer 251 
sequences revealed an additive effect of the motifs, resulting in an increased translational 252 
defect in cells expressing low levels on SMN (Fig. 5j and Extended data 5i).In summary, 253 
these findings demonstrate that a combination of two features is required for SMN-specific 254 
mRNAs to be controlled translationally: i) translational enhancer sequences in the 5’UTR, 255 
and ii) rare codons  in the first five codons of the CDS. 256 
 257 




To further validate the role of ribosome-associated defects in SMA pathogenesis, we 260 
explored the effect of SMN loss on transcripts belonging to the seven SMN-specific 261 
communities previously identified (Fig. 3f). Transcripts belonging to all the seven 262 
communities have a significantly decreased ribosome occupancy at early stage of the 263 
disease (Fig. 6a). This effect is not caused by transcriptional down-regulation (Extended 264 
data Fig. 6a). The communities are also enriched in transcripts reported to be down-265 
regulated in SMA (community 3, Translation/Ribosome) and ALS (community 1, 266 
Axon/Cytoskeleton and 2 Synapse/Vesicle) (Fig. 6b).  267 
According to these and previous results (Fig. 4 and 5), SMN-dependent translational 268 
defects are compatible with a loss of SMN-primed ribosomes along the CDS of SMN-specific 269 
transcripts. To test this further, we performed a co-sedimentation analysis of SMN-specific 270 
mRNAs along sucrose gradients of control and early symptomatic mouse brain (Extended 271 
data Fig. 6b), selected from the five most abundant communities (Supplementary Table 3 272 
and Extended data Fig. 6c). Tuba4a and Acca2, chosen as controls, did not show any 273 
change (Fig. 6c). Indeed, we confirmed that at early stage of disease transcripts belonging 274 
to communities 1, 2, 3 and 5 are depleted from polysomal fractions, shifting towards 275 
ribosome-free fractions (Fig. 6d-g and i) and leading to possible changes at the protein level 276 
(Fig. 6f). Two histone transcripts, representatives of community 4, showed an accumulation 277 
on polysomes in parallel to a decrease in the occupancy in active ribosomes by using 278 
RiboLace (Fig. 6a). A plausible explanation is that inactive ribosomes might be stalled along 279 
the histone transcripts, leading to a decrease in protein production in SMA, as previously 280 
shown for several histones (39). 281 
Overall, these results support our genome-wide findings and suggest that SMN-282 
specific transcripts are depleted of ribosomes in SMA. 283 
 284 
Acetylcholinesterase mRNA is an SMN-specific transcript and an early marker of local 285 
defects at the NMJ in SMA 286 
Next, we further characterized a neuron-specific gene, belonging to the larger SMN 287 
community (Axon/Cytoskeleton): acetylcholinesterase (AChE). This transcript displays a 288 
significant decrease in translational efficiency in both brain and spinal cord (Extended data 289 
Fig. 7a). Importantly, in SMA mice treated with a single injection of ASO which restores SMN 290 
levels (11), AChE expression was restored to control levels, supporting a direct relationship 291 
between AChE and SMN levels (Extended data Fig. 7a). To confirm that the 5’ UTR and 292 
the sequence of the first five amino-acids of the AChE transcript are associated with 293 
translational defects under SMA-like conditions in cellulo, we performed two luciferase 294 
assays (Fig. 7a-b and Extended data Fig. 7b-c). For both these functional motifs, we 295 
confirmed that loss of SMN expression causes translational defects in protein production of 296 
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the reporter genes (Fig. 7a-b). In addition, we observed that at an early stage of disease the 297 
AChE transcript is depleted from polysomal fractions, shifting towards the ribosome-free 298 
fractions (Fig. 7c). In agreement with these results, we observed that AchE protein 299 
expression was decreased at both early and late stages of SMA in several tissues (Fig. 7d-f 300 
and Extended data Fig. 7d). Moreover, local expression of AChE protein was significantly 301 
impaired at the neuromuscular junction (NMJ) in symptomatic SMA mice (Fig. 7g and h), 302 
whilst acetylcholine receptor (AChR) expression remained unchanged (Fig. 7g and h). 303 
Downregulation of AChE protein at the NMJ temporally follows the translational defect in 304 
ribosome occupancy at earlier stages (Extended data Fig. 7e-f), serving as a molecular 305 
marker of impairment at the NMJ in SMA.  306 
 307 
Discussion 308 
This study provides experimental evidence supporting the hypothesis that SMN is a 309 
ribosome-associated protein, demonstrating that SMN can be found in two distinct functional 310 
‘populations’ within the cytoplasm. One population is associated with the well-known, 311 
canonical role of SMN in RNP biogenesis via its association with Gemin granules (40, 51). In 312 
line with Jablonka et al. (52) we found a second population that was not associated with 313 
Gemin granules, but rather with ribosomes. We show that SMN as a ribosome-associated 314 
protein in vitro and in vivo, in agreement with the known ability of SMN to co-sediment with 315 
polysomes in vivo, in cellulo and in vitro (11, 28–30), as well as with general factors of 316 
translation such as eEF1A (53). Strikingly, the population of ribosomes associated with SMN 317 
(SMN-primed ribosomes), only made up a small fraction of the total ribosome pool. SMN-318 
primed ribosomes display two unique characteristics: i) they are associated with a specific 319 
subset of mRNAs which form functionally related communities, and; ii) they are preferentially 320 
placed within the first five codons of the CDS.  321 
SMN-primed ribosomes bind mRNAs characterized by strong enrichment in rare 322 
codons at the beginning of the CDS, particularly arginine-codons, and in translational 323 
enhancer sequences in the 5’UTR. The ability to associate with a subset of mRNAs has 324 
previously been observed for ribosomes containing particular ribosomal proteins (15, 20). 325 
Notably, we found that a significant number of mRNAs bound by SMN-primed ribosomes 326 
have previously been linked to the pathogenesis of SMA, as well as to related 327 
neuromuscular conditions such as ALS. This provides a possible molecular explanation as to 328 
why defects in ubiquitously-expressed proteins, such as SMN, can lead to the specific 329 
sensitivity to degeneration of motor neurons in conditions such as SMA and ALS.  330 
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The fact that SMN-primed ribosomes are located within the first codons of SMN-331 
specific transcripts suggests a highly specific, local function for this defined subpopulation of 332 
ribosomes. It has been observed that a ribosome-pause at these first codons acts as a 333 
translational checkpoint to ensure productive ribosome elongation and protein synthesis 334 
(54). Accordingly, SMN binds to the elongation factor eEF1A (53). We found that SMN is 335 
required for productive translation and that the positive regulation of translation is lost when 336 
SMN expression is reduced (11, 28, 30). In addition, we found two distinct populations of 337 
mRNA fragments protected by SMN-primed ribosomes characterized by different lengths. 338 
Similar bimodal distributions in read lengths have been observed in yeast, and have been 339 
associated with diverse structural conformations of the ribosome during translation 340 
elongation (37, 55). Further investigation of these ribosome conformations may require the 341 
use of diverse translation inhibitors, similar to Wu et al. (56). By profiling actively translating 342 
ribosomes (36) in control and early symptomatic SMA tissues we found that the vast majority 343 
of genes associated with a significant variation in ribosome occupancy displayed a strong 344 
decrease in active ribosomes numbers upon SMN depletion. The mRNAs associated with 345 
SMN-primed ribosomes showed profound positional defects at beginning of the CDS, 346 
suggesting a possible loss of specific ribosome recruitment or pausing mediated by SMN-347 
primed ribosomes at a critical initial step during translation, leading to ribosome drop off (54). 348 
Thus, we propose a model whereby SMN regulates the translation of rare codons by acting 349 
as a stabilizer of specific ribosome conformations at the beginning of the CDS, where it can 350 
induce a functional ribosome slowdown that ensures productive translation (Extended data 351 
Fig. 8). 352 
Among the mRNAs bound by SMN-primed ribosomes and characterized by 353 
translational defects in SMA, we identified acetylcholinesterase (AChE) whose 5’UTR and 354 
first 5 codons are translationally sensitive to low levels of SMN expression. AChE performs a 355 
central role in NMJ function by turning over acetylcholine after it has been used for signal 356 
transduction by motor neurons. Dysfunction and denervation of the NMJ is one of the 357 
earliest pathological features of SMA (57–59). In agreement with our proposed model, we 358 
found that, in early symptomatic SMA, the recruitment of AChE mRNA on polysomes is 359 
reduced, resulting in defects at the protein level in SMA-related tissues and at the NMJ at 360 
later stages of disease. Previously, an absence of the asymmetric A12 form of AChE was 361 
observed in the serum of SMA Type I patients (60). Moreover, mutations affecting AChE in 362 
humans cause congenital endplate acetylcholinesterase deficiency, a disease displaying a 363 
number of clinical features overlapping with those observed in SMA (61). Thus, SMN-primed 364 
ribosomes play a crucial role in regulating AChE levels that are likely to contribute to NMJ 365 
defects at the core of SMA pathogenesis.  366 
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The robust influence of SMN levels on ribosome binding, alongside the higher 367 
relative concentration of SMN protein found in the nervous system (34), supports a model 368 
whereby a stronger effect on transcripts bound by SMN-primed ribosomes should be 369 
observed in these tissues. Thus, a different scenario for better understanding the molecular 370 
pathogenesis of SMA can be generated, in which tissue- and concentration-specific 371 
regulation of SMN concertedly tune the correct translation of mRNAs bound by SMN-primed 372 
ribosomes, as illustrated here by the effect observed on AChE.  373 
Taken together, our findings demonstrate a central role for SMN in the regulation of 374 
ribosome heterogeneity, acting as a master modulator of ribosome fluxes on a disease-375 
specific subset of disease-relevant mRNAs characterized by specific sequence features. 376 
This reveals an important role for ribosome-associated proteins in the regulation of tissue-377 
specific disease pathogenesis in SMA and related conditions.  378 
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Figure legends 611 
 612 
Fig. 1| SMN interacts with the translation machinery in vitro and in vivo in an RNA-independent 613 
manner. a, Schematic overview of experimental design for studying the binding of recombinant SMN 614 
to purified SMN-free ribosomes, used for downstream binding analysis: i) Surface Plasmon 615 
Resonance (SPR) and ii) ultracentrifugation analysis to separate bound and unbound SMN which 616 
were analyzed by western blotting. b, Typical SPR titration curves were used to estimate the KD 617 
(ka=9.7±4.8 × 10
6 M-1s-1, kd=9.4±5 × 10
-5 s-1, KD=9.8±2.8 × 10
-12 M, values are the average ± SD, n=6 618 
independent experiments) Typical SPR curve: black line indicates the titration, the red line indicates 619 
fitting for 1:1 binding model. c, Western blotting of unbound and ribosome-associated SMN at different 620 
SMN concentrations. The concentration of ribosomes was constant in all experiments. Representative 621 
example of 3 independent experiments. Immunoblots were acquired at short (SMNs) and long (SMNl) 622 
exposure times. d, Schematic overview of the subcellular fractionation protocol used to study the 623 
association of SMN to ribosomes in brain and spinal cord. e, Western blot analysis on cytoplasmic 624 
lysates from brain; input; ribosome-free cytoplasmic components (unbound); ribosomal subunits, 625 
ribosomes and polysomes (R-pellet); loosely ribosome-bound proteins (LBR); strongly ribosome-626 
bound proteins (SBR). PABP and eIF2a are proteins associated to polysomes and HuD is an RNA 627 
binding protein associated with polysomes through RNA interactions. The ribosomal proteins L26 and 628 
S6 were used as control of ribosome sedimentation. The results are representative of 3 independent 629 
experiments. f, The ribo-pellet was treated with RNase I and ultracentrifuged to separate proteins 630 
interacting with ribosomes through RNA-dependent or independent interactions. The RNA binding 631 
proteins HuD and QKI were used as controls for RNA-dependent interactions. g, Schematic of 632 
immunoprecipitation of SMN from purified polysomal fractions (upper panel). The first wash 633 
corresponds to the “unbound” lane. After on beads RNase treatment, proteins were extracted from 634 
beads (Protein-mediated) or from washes (RNA-mediated). The IP was performed on sucrose 635 
fractions corresponding to polysomes in brain P5 with anti-SMN or mouse IgG as control (lower 636 
panel). The results are representative of 2 independent experiments. Statistical source data and 637 
unprocessed blots are provided in Source data Fig. 1. 638 
 639 
 640 
Fig. 2| SMN interacts with the translation machinery in a concentration dependent manner 641 
across different tissues and is associated to actively translating ribosomes positively 642 
regulating translation. Co-sedimentation profiles of SMN in a, brain and b, liver. The relative 643 
distributions of SMN, and markers of the small (RPS6) and large (RPL26) subunits of the ribosome 644 
were used as controls for sedimentation (upper panels). The relative distribution of each protein along 645 
the profile is shown as the average ± SEM of n=3 biologically independent experiments. Immunoblots 646 
were acquired at short (SMNs) and long (SMNl) exposure time. c, Summary of SMN co-sedimentation 647 
with RNPs, 60S, 80S and polysomes in different tissues. The percentages are shown as the average ± 648 
SEM of n=3 biologically independent experiments and were obtained using co-sedimentation profiles 649 
shown in panels (a, b and Extended data Fig.2b-d). d, Relationship between the relative expression 650 
level of SMN in different tissues from (34) and the relative distribution of SMN in RNPs, 60S, 80S and 651 
polysomes obtained from (c). Data are presented as the average ± SEM of n=3 biologically 652 
independent experiments. e, In vitro translation of reporter GFP in the presence of different 653 
concentrations of recombinant SMN. As a negative control a reaction in the absence of the GFP 654 
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reporter was run in parallel. RPL26 was used as a loading control. Left lower panel, semi-quantitative 655 
analysis of GFP level in the presence of different concentrations of recombinant SMN. Plotted are the 656 
averages ± SEM from n=3 independent experiments. Right lower panel, the production of GFP was 657 
monitored by measuring the appearance of fluorescence in independent assays. f, Western blot 658 
analysis of SMN association to active ribosomes using RiboLace (36) in human cells (upper panels) 659 
before and after treatment with the translation inhibitor puromycin (100 μM, 1h). RPL26 is used as a 660 
marker of ribosomes. The enrichment of SMN and RPL26 with respect to the not-functionalized beads 661 
is shown. Plotted are the average ± SEM for n=4 (SMN) and n=3 (RPL26) biologically independent 662 
experiments. Significant changes were assessed using a two-sided t-test. Statistical source data and 663 
unprocessed blots are provided in Source data Fig. 2. 664 
 665 
Fig. 3| Ribosome profiling of SMN-primed ribosomes reveals enriched mRNAs organized in 666 
functionally well-defined communities. a, Schematic representation of the protocol used to isolate 667 
RNA fragments protected by ribosomes associated with SMN. b, Positional enrichment along the three 668 
mRNA regions of SMN-specific RiboSeq reads. The bar plots display the percentage of reads aligning 669 
on 5’ UTR, CDS and 3’ UTR for SMN-specific RiboSeq, RiboSeq and classical sequencing of 670 
polysomal transcripts (PolSeq from (11)) as control. c, Overlay meta-profiles for mRNAs enriched in 671 
SMN-bound RPFs based on the P-site position of SMN-primed ribosomes (blue) and total ribosomes 672 
(gray) for n=3 and n=2 biologically independent samples, respectively. The line represents the 673 
average ± SEM. Differences were tested using the two-sided t-test (p-values corresponding to codons 674 
6 and 8-13 are: 0.0021, 0.0051, 0.0018, 0.0006, 0.0480, 0.0017, 0.0280). d, Left panel: distribution of 675 
read lengths, fitted with two Gaussian curves. Right panels: meta-profiles based on the P-sites of short 676 
reads (24-26 nucleotides, upper panel) and long reads (32-34 nucleotides, lower panel). Data are 677 
presented as the average ± SEM of n=3 biologically independent samples. e, Dot plots showing the 678 
distributions of the ratios between the average number of P-sites on the first five codons (initiation) 679 
and the average number of P-sites on the whole coding sequence (CDS) for SMN-specific RiboSeq 680 
(n=874 transcripts) and classical RiboSeq (n=704 transcripts) in control mouse brain. Statistical 681 
significance was determined using the two-sided Wilcoxon-Mann-Whitney test. f, Representative 682 
protein interaction network of SMN-specific transcripts. Connections are based on STRING annotation 683 
and weighted by interaction score. Connectivity analysis of the full network identified seven 684 
communities characterized by high intra connectivity and color-labelled. The insert reports the name 685 
and the number of SMN-specific genes in each community. Statistical source data are provided in 686 
Source data Fig. 3. 687 
 688 
Fig. 4| Transcripts bound by SMN-primed ribosomes display defects in positioning of active 689 
ribosomes at early stages of SMA. a, Experimental design for active ribosome profiling (RiboLace) 690 
of control and early symptomatic SMA brains. b, Number of genes with significantly increased (up) or 691 
decreased (down) active ribosome occupancies in early symptomatic SMA mouse brain. c, Over-692 
representation analysis of terms associated with motor neuron diseases among genes enriched in 693 
SMN-primed ribosomes (SMN specific, blue) and genes with decreased translation occupancy in SMA 694 
(SMA down, red). Genes with increased translation occupancy in SMA did not show any significant 695 
enrichment for terms associated with motor neuron diseases. d, Comparison between SMA active 696 
ribosome occupancy changes in SMN-specific genes (red, n=554 genes) and SMN unspecific genes 697 
(grey, n=13178 genes). SMN specific genes show a significant shift towards a reduction in SMA active 698 
ribosome occupancy (two-sided Wilcoxon rank-sum test). e, Dot plots showing the ratio distribution 699 
between the average number of P-sites on the first five codons (initiation) and the average number of 700 
P-sites on the whole coding sequence (CDS) for SMN-specific transcripts based on signal from SMN-701 
specific RiboSeq (blue, n=874 transcripts), control and SMA Active-RiboSeq (gray and red, n=859 and 702 
n=774 transcripts respectively). Significant differences were determined using the two-sided Wilcoxon-703 
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Mann-Whitney test. Corresponding distributions are displayed on the right of the plot. Statistical source 704 
data are provided in Source data Fig. 4. 705 
 706 
Fig. 5| Translationally defective transcripts in SMA display specific features. a, Over-707 
representation of translational enhancers in genes with significantly increased (yellow, 287) or 708 
decreased (red, 835) ribosome occupancies in SMA. Two-sided Fisher's test p-value is shown. b, 709 
Over-representation of translational enhancers in SMN-specific genes with defects in ribosome 710 
occupancy in SMA (blue, 52). The two-sided Fisher's test p-value is shown. c, Comparison between 711 
the codon usage index, based on the P-sites signal in control and SMA Active-RiboSeq. Each dot 712 
represents a codon and is colored according to the amino-acid frequency in the transcriptome, divided 713 
in 5 classes (low: rare codons; high: frequent codons). Regression line, its 99% confidence level 714 
interval and Pearson correlation coefficient are displayed. The 10 furthest points from the confidence 715 
level are labelled. d, List of triplet, corresponding amino-acid and distance from the regression line of 716 
codons. Negative values correspond to codons whose P-site coverage is lower in SMA than in CTRL, 717 
positive values correspond to opposite coverage. e, Logo-like representation of the most frequent 718 
amino-acids in SMN-specific mRNAs with significant alterations in ribosome occupancy in SMA at the 719 
beginning of the CDS. Letters are colored as in b. f, Luciferase assays are shown as the ratio between 720 
Fluc and Rluc normalized to the results obtained with the frequent alanine repeats vector. g, Diagram 721 
summarizing the feature combinations in the 5’UTR and CDS of SMN-specific transcripts with 722 
translational defects in SMA. h, Luciferase assays are shown as the ratio between Fluc and Rluc 723 
normalized to the alanine vector. i, Luciferase assays for the translational enhancer sequence within 724 
the 5’UTR of cMyc. j, Luciferase assays for testing the synergic contribution of the features in h and i. 725 
For all the luciferase assays the results are normalized for the values in the SMN high expression 726 
cells, that were set to 1. The number of biologically independent experiments is reported in the graph. 727 
Results are shown as the average ± SEM. Significant changes were assessed using one-sided t-test. 728 
Statistical source data are provided in Source data Fig. 5. 729 
 730 
Fig. 6| Communities of mRNAs bound by SMN-primed ribosomes show reduced ribosome 731 
occupancy. a, Comparison between SMA active ribosome occupancy changes in SMN-specific 732 
genes, binned in the 7 SMN-communities. All the communities show a significant shift towards a 733 
reduction in SMA active ribosome occupancy (Two-sided one-sample Wilcoxon rank-sum test, ** p-734 
value <0.01; *** p-value <0.001). The number of genes for each community is reported in Fig. 3f. b, 735 
Over-representation analysis of terms associated with motor neuron diseases among SMN-specific 736 
genes belonging to the 7 SMN-communities. The heatmap is colored according to the significance of 737 
the enrichments. c, Relative co-sedimentation profile of SMN unspecific transcripts, Tuba4a and 738 
Acca2 along the sucrose gradient fractions of control (gray lines) and early symptomatic (red lines) 739 
brains. Data are represented as average ± SEM among n=3 biologically independent samples. d-e, 740 
Relative co-sedimentation profile of mRNAs bound by SMN-primed ribosomes and belonging to the 741 
community 1 (ChgA and Slc17a6) and 2 (Peg3 and Get4). Data are represented as average ± SEM 742 
among n=3 biologically independent samples. One-sided t-test, * p <0.05; ** p <0.01. f, Lysates of 743 
brain of late-symptomatic SMA mice were compared to age-matched littermate controls using western 744 
blot. Quantification of immunoblot for GET4 was normalized to total protein stain. SMA expression 745 
values are normalized and compared to control values for each of the tissues. Data are represented 746 
as average ± SEM among n=4 biologically independent samples. Significant changes were assessed 747 
using a two-sided t-test. g-i, Relative co-sedimentation profile of mRNAs bound by SMN-primed 748 
ribosomes and belonging to the community 3 (Rpl14), 4 (Hist1h3i and Hist1h3c) and 5 (Gatd3a). Data 749 
are represented as average ± SEM among n=3 biologically independent samples. One-sided t-test, * 750 
p-value <0.05; ** p-value <0.01. Statistical source data and unprocessed blots are provided in Source 751 





Fig. 7| The acetylcholinesterase transcript shows ribosome drop-off and defective production 755 
of protein at the NMJ in SMA. a, Luciferase assays with a reporter bearing the 5’UTR of Ache. The 756 
5’UTR of Tuba4a was used as control. Results are shown as the average ± SEM, n is shown in the 757 
graph Significant changes between cell lines were assessed using the one-sided t-test. b, Luciferase 758 
assays for testing the contribution of the first five codons of AChE. Upper panel, representation of the 759 
reporter. The experiment was performed as in Fig. 5g and 5h. Results are shown as the average ± 760 
SEM, n is shown in the graph. Significant changes were assessed using a one-sided t-test. c, Relative 761 
co-sedimentation profile of AChE mRNA in control (gray) and early symptomatic (red) brains. Data are 762 
represented as average ± SEM among n=3 biologically independent samples. d, Protein levels in 763 
brain, spinal cord and muscle of late-symptomatic SMA mice were compared to controls using western 764 
blot. e, Quantification of immunoblots for AChE normalized to total protein stain at early-symptomatic 765 
stage. Data are represented as average ± SEM among n=3 biologically independent samples. 766 
Significant changes were assessed using a two-sided t-test. f, Quantification of immunoblots for AChE 767 
normalized to total protein stain at late-symptomatic stage SMA Data are represented as average ± 768 
SEM among n=3 biologically independent samples. Significant changes were assessed using the two-769 
sided t-test. g, g, Representative images for control and late-symptomatic SMA mouse neuromuscular 770 
endplates. Acetylcholine receptors were labelled using alpha-bungarotoxin (BTX) and AChE was 771 
labelled using fasciculin-2 (FCC). A total of 77 endplates from control and 93 endplates from SMA 772 
mice taken from 6 muscles and 3 mice per genotype were imaged and analysed. Scale bar: 10 μm. h, 773 
FCC and BTX average intensity were determined for 2 FDB muscles in 3 control and 3 SMA 774 
biologically independent mice. N in graph indicates the number of analysed endplates per mouse. 775 
Data are represented as average ± SEM. Significant changes were assessed using a two-sided t-test. 776 
Statistical source data and unprocessed blots are provided in Source data Fig. 7. 777 
 778 
Materials and Methods 1 
  2 
Animal models 3 
Animal procedures and breeding were performed in accordance with University of 4 
Edinburgh institutional guidelines and under appropriate project and personal licenses granted 5 
by the UK Home Office (PPL: P92BB9F93). The ‘Taiwanese’ mouse model of severe SMA (62), 6 
on a congenic FVB background, was established from breeding pairs originally purchased from 7 
Jackson Labs and maintained following an established breeding strategy (63). Phenotypically 8 
normal littermates (Smn+/-;SMN2tg/0) were used as controls. Litters were genotyped using 9 
standard protocols. All mice were housed within the animal care facilities in Edinburgh under 10 
standard SPF conditions. For clarity, throughout the paper we refer to the time points at which 11 
tissue was collected as early and late symptomatic. Early symptomatic was postnatal day 5 (P5) 12 
and late symptomatic was P7. All tissues were quickly dissected, snap-frozen and stored at -13 
80°C until use.  14 
  15 
Subcellular fractionation from tissues 16 
The method was adapted from Francisco-Velilla et al., 2016 (31). Lysates from brain or 17 
spinal cord were obtained as in (11). A few µL of the lysate was kept for protein extraction 18 
(input). The sample was centrifuged for 67 min at 100,000 rpm using a TLA100.2 rotor 19 
(Beckman). Supernatant corresponds to proteins not associated to ribosomes or polysomes 20 
(unbound). The pellet containing ribosomes, (R pellet) was solubilized in 15 mM Tris-HCl pH 21 
7.4, 100 mM KCl, 5 mM MgCl2, 2 mM DTT, 290 mM sucrose and few µL were kept for protein 22 
extraction. The remaining volume was adjusted to 500 mM KCl, to detach mildly associated 23 
proteins. The sample was loaded on a discontinuous sucrose gradient (720 μL buffer 40% (w/v) 24 
sucrose, 15 mM Tris-HCl pH 7.4, 500 mM KCl, 5 mM MgCl2, 2 mM DTT (bottom layer) and 480 25 
μl buffer 20% (w/v) sucrose, 15 mM Tris-HCl pH 7.4, 500 mM KCl, 5 mM MgCl2, 2 mM DTT (top 26 
layer) and ultra-centrifuged at 100,000 rpm or 1.5 h using a TLA100.2 rotor (Beckman). 27 
Supernatants contain proteins loosely associated to ribosomes and polysomes (LBR), the pellet 28 
contains washed ribosomes (RBR). The pellet was dissolved in sample buffer, proteins in the 29 
other fractions were extracted using a Methanol/Chloroform protocol. RNAse treatment: the R-30 
pellet was prepared as described above was treated with RNAse I (1.5U/1Abs260) for 45 min at 31 
rt. The lysate was ultracentrifuged as above to isolate the proteins associated to 32 
ribosomes/polysomes via RNA-dependent interactions and proteins associated via protein-33 
dependent interactions. Protein extraction was performed as above before analysis by western 34 
blotting. The following primary antibodies were used: RPS6 (Cell Signaling; AB_331355 35 
(1:1000)); RPL26 (Abcam; AB_945306 (1:1500)); SMN (BD Transduction Laboratories; 610646 36 
(1:1000)); HuD (Santa Cruz Biotechnology (1:1000)); QKI (Abcam Ab-126742 (1:1000)). The 37 
following secondary antibodies were used: anti-Mouse HRP (Santa Cruz Biotechnology; Sc-38 
2357 (1:3000)); anti-Rabbit HRP (Santa Cruz Biotechnology; Sc-2004 (1:3000)). 39 
 40 
Western blotting from tissues 41 
Western blot on tissues from SMA and control mice was performed exactly as described 42 
before (64). The following primary antibodies were used 4E-BP (Abcam; Ab-2606 (1:1000)); P-43 
4E-BP (Abcam; Ab-27792 (1:1000)); eIF2α (Santa Cruz Biotechnology; Sc-11386 (1:1000)); p-44 
eIF2α (Abcam; Ab32157 (1:1000)); Get4 (Proteintech 27768-1-AP (1:1000)); AE2 45 
(acetylcholinesterase) (DSHB AE2DSHB (1:1000)). Antibody detection was performed using 46 
fluorescent secondary antibodies (LI-COR) and protein loading was normalized to a fluorescent 47 
total protein stain (LI-COR). Quantification was performed as described previously (34).  48 
 49 
Ribosome purification and ribosome-binding assay 50 
Purification of 80S ribosomes was performed from NSC-34 depleted from SMN using 51 
CRISPR-Cas9 technology (11). The lysate was treated with RNase I (7.5 Units /1 Abs260 52 
lysate) at RT for 45 min and analyzed by sucrose gradient (10-40%) (65). The fraction 53 
corresponding to the 80S was collected and 2mM DTT was added. After centrifugation at 54 
90,000 rpm for 4 h using a TLA100.2 rotor (Beckmann) the pellet was resuspended in 10 mM 55 
Tris-HCl pH 7.5, 10 mM MgCl2, 150 mM NaCl, 2 mM DTT, 100 μg/mL cycloheximide and stored 56 
at −80°C. Ribosome concentration was calculated as in (66). Recombinant SMN was purchased 57 
(ENZO) and incubated with ribosomes for 2 h at 4°C. SMN bound ribosomes were purified from 58 
unbound SMN by ultracentrifugation at 90,000 rpm for 4 h using the TLA100.2 rotor on 30% 59 
sucrose cushion. The supernatant was kept for protein purification by using the 60 
chloroform/methanol protocol and the pellet was directly dissolved in sample buffer (Santa 61 
Cruz), heated at 99°C for 10 min and resolved by SDS-PAGE. SMN and  RPL26, were detected 62 
using primary and secondary antibodies described above. 63 
 64 
Surface Plasmon Resonance 65 
Surface plasmon resonance (SPR) experiments were carried out using a Biacore X100 66 
(GE Healthcare, US). Binding experiments were done at 22 °C in 20 mM Hepes-NaOH, pH 7.4, 67 
150 mM NaCl, 5mM MgCl2, and 0.005 % surfactant P20 as a running buffer. SMN protein was 68 
immobilized on C1 sensor chip (GE Healthcare, US) via amine coupling following 69 
manufacturer's recommended procedure. The carboxymethyl dextran surface was activated 70 
with a 7-min injection at 5 µl/min of a 1:1 ratio of 0.4 M 1-ethy-3-(3-71 
dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 0.1 M N-hydroxy succinimide 72 
(NHS). Buffer without the protein was injected over the flow cell 1, as a reference for subtraction 73 
from the binding signal obtained in experiments on flow cell 2, where SMN was immobilized. 74 
Residual reactive sites on the surface of the sensor chip were deactivated with a 7-min injection 75 
of 1 M ethanolamine, pH 8.5. A series of ribosome concentrations, typically ranging from 0.4-10 76 
nM were injected over immobilized SMN protein at a constant flow rate 80 µl/min for 1 min. 77 
Ribosome dissociation was monitored for 300 s, followed by the injection of 0.1 M glycine-78 
NaOH, pH 12, and 0.3 % Triton X100 for 11 s at 80 µl/min for the regeneration of the surface. 79 
Sensorgrams were processed with BiaEvaluation software (GE Healthcare, US). The average 80 
response of blank injections was subtracted from all analyte injections. Kinetic parameters were 81 
determined from the processed data by globally fitting ka and kd to a 1:1 binding model. Six 82 
independent estimations of KD were done and the results shown are the average KD ± SD, n = 83 
6. 84 
 85 
In vitro transcription-translation assays 86 
In vitro transcription-translation was performed using the 1-Step Human Coupled IVT Kit 87 
HeLa lysates and pCFE-GFP as reporter (Thermo Scientific). GFP protein quantifications were 88 
performed by western blotting and fluorescence spectroscopy. For western blotting, after 89 
incubation of each reaction at 30°C for 1.5 h, proteins were extracted, solubilized in sample 90 
buffer and analyzed by SDS-PAGE. The production of EGFP was monitored using an 91 
TurboGFP Thermo Scientific (1:1000). SMN was monitored using SMN BD Transduction 92 
Laboratories 6 (1:1000). RPL26 was used as control. Protein production was quantified by 93 
densitometric analysis using ImageJ. The EGFP signal was normalized to the RPL26 signal. 94 
The GFP production by fluorescence spectroscopy was monitored following the height of the 95 
emission spectra maximum at 502 nm. 10 µL sample after 1.5 h incubation at 30°C in the 96 
presence of different SMN concentrations  was added to a 1-cm quartz cuvette filled with 990 µL 97 
of buffer. Spectra were acquired on a Fluoromax-4 (Horiba Jobin-Yvon) with lex=482 nm.  98 
 99 
Immunoprecipitation of SMN-associated proteins from polysomal fractions and ribosomal pellets 100 
IP from polysomal fractions was performed on pooled polysomal fractions from control 101 
brains (11). Samples were diluted 3x using 30 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM 102 
MgCl2, 20 μL/mL cycloheximide. One mL was kept as input, and the remaining sample was 103 
divided into two parts and incubated for 2 h at 4 °C with either 2 μg of SMN antibody (BD 104 
Biosciences) or, as negative control, 2 μg of anti-Mouse IgG (Abcam) while rotating. Dynabeads 105 
Protein G and Dynabeads Protein A (Life Technologies) were added and kept rotating for 2h at 106 
4 °C. The supernatant was stored as “Unbound”. Beads were washed 3x with 500 μL Washing 107 
Buffer (10 mM Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM NaCl, 1% Triton X-100, 1 mM DTT, 0.2 108 
mg/mL cycloheximide, 1% Na-deoxycholate, 2.5 μL/mL Protease Inhibitor Cocktail). RNase 109 
A/T1 was added (200 μg/mL final concentration) and the samples kept under rotation for 1.5 h 110 
at 4 °C. Samples were placed on the magnetic stand and the supernatant stored. Next proteins 111 
(“RNA-mediated”) were extracted. After extensive washing, proteins on the beads (“Protein-112 
mediated”) were dissolved in sample buffer for western blotting. All other samples (“Input”, “RNA 113 
mediated” and “Unbound”) were purified by methanol/chloroform extraction and analyzed by 114 
western blotting. The primary antibodies described against the following proteins were used: 115 
SMN, RPS6; RPL26;  eIF4A1 (Abcam; AB_732122 (1:1000)); PABP (Abcam; AB_777008 116 
1:1000).  117 
 118 
Polysomal profiling and co-sedimentation analysis of proteins 119 
Cytoplasmic lysates from cell lines (NSC-34 and Hek-293) or frozen mouse tissues or 120 
cells were prepared as described previously (11). Lysates were loaded on a sucrose gradient 121 
(10-40% sucrose [m/v], in 100 mM NaCl, 10 mM MgCl2, 10 mM Tris/HCl pH 7.5) and 122 
ultracentrifuged for 1.5 h at 198,000 g at 4°C in a Beckman Optima™ LE-80K Ultracentrifuge. 123 
One ml fractions were collected monitoring the absorbance at 254 nm with an ISCO UA-6 UV 124 
detector. For Mg2+ depletion, cells were lysed in 10 mM NaCl, 10 mM Tris/HCl pH 7.5, 1% 125 
Triton-X, 1% Na-deoxycholate and loaded on sucrose gradients prepared in 100 mM NaCl, 10 126 
mM Tris/HCl pH 7.5. 127 
Proteins were extracted using the methanol/chloroform protocol (67) and solubilized in 128 
Sample Buffer (Santa Cruz Biotechnology) for the SDS-PAGE and western blotting. The 129 
following primary antibodies were used anti RPS6; RPL26, SMN and Gemin5 (Novusbio; 130 
NB100-61049 (1:1000)); HuR (Santa Cruz Biotechnology Sc-71290 (1:1000)). The secondary 131 
antibodies were used as above.  132 
The co-sedimentation profiles of proteins along the sucrose gradient, was obtained as 133 
described in (11). The relative percentage of the protein intensity of each fraction along the 134 
sucrose gradient was calculated as follows: 135 
% Proteinn= [Protein]n/Σn=0->12 [Protein]n 136 
where % Proteinn is the percentage of the protein in the fraction n; [Protein]n is the 137 
density of the protein in the fraction n and 12 is the total number of fractions. 138 
 139 
Cloning of 5’UTRs and SMN-specific motifs and Luciferase assay 140 
pGL3 plasmid was used to generate monocistronic reporters. Sequences for the first five 141 
amino-acids of the Firefly luciferase CDS were introduced by complementary oligonucleotides 142 
designed to form overhangs corresponding to HindIII and NcoI restriction sites. pRuF plasmid 143 
was used to create bicistronic luciferase reporters to study AchE, Tuba4a, or cMYC 5'-UTRs, 144 
that were PCR-amplified from cDNAs from mouse brain (P5), or from an available plasmid, 145 
using suitable cloning primers (Supplementary Table 4). In the pRuF vector, Renilla and Firefly 146 
cDNAs are transcribed as a single transcript separated by the cloned 5′-UTR sequences. pRuF 147 
plasmids were further modified to study the combined effect of 5’UTR and first five amino-acids, 148 
inserted by exploiting the restriction sites PmlI and NarI. All plasmid clones were checked by 149 
DNA sequencing. 150 
NSC-34 expressing high or low levels of SMN (11) were seeded in 24-well plates and 151 
co-transfected with 3:1 ratio (300ng + 100ng) of pGL3 and pRLSV40 plasmid -to normalize for 152 
transfection efficiency- or with 400ng pRuF plasmids using TurboFect Transfection Reagent 153 
(Thermo Scientific). Luciferase assays were run 48h after transfection, using the dual-luciferase 154 
reagent (Promega) as in (65). Total RNA was extracted by TRIZOL from lysates from the 155 
lysates used for dual luciferase assays to determine the expression level of luciferase reporters. 156 
cDNA was synthesized from 100 ng RNA using the RevertAid First Strand cDNA synthesis kit 157 
(Thermo Scientific). qPCR was carried out using Kapa Syber Fast qPCR Mastermix (Kapa 158 
Biosystems) and specific primers (Supplementary Table 5). 18S was used as reference gene. 159 
 160 
Immunoprecipitation of SMN with active ribosomes 161 
Control MCF7 cells and MCF7 cells treated with puromycin 100 µM for 1h were lysed 162 
according to (36). Active ribosomes were isolated using RiboLace kit (IMMAGINA 163 
Biotechnology). Proteins were extracted from beads using sample buffer (Santa Cruz). Five µL 164 
of lysate were kept as input. Proteins were resolved using SDS-PAGE and western blotting as 165 
in (36).  166 
 167 
Active and classical Ribosome profiling 168 
Cytoplasmic lysates from P5 control and early symptomatic SMA mouse brains were prepared 169 
as in (11). For Active-ribosome profiling, RiboLace kit (IMMAGINA Biotechnology) was used 170 
following manufacturer’s instructions. The libraries quality and quantity were assessed by using 171 
the high-sensitivity DNA chip on the BioAnalyzer (Agilent) according to the manufacturer’s 172 
protocol and Qubit® 2.0 (ThermoFisher Scientific). The libraries were sequenced on an Illumina 173 
HiSeq2500. Ribosome profiling from control P5 brains was performed after polysomal 174 
purification. Polysomes were purified as described above. Polysomal fractions were pooled and 175 
digested with Rnase I (150U/unit of area of polysomes, calculated from the polysomes profile) 176 
for 2h at 4°C. The digestion was stopped by 400 U SUPERase-In RNase inhibitor (Thermo 177 
Fisher Scientific). RNA was extracted as in Bernabò et al., 2017(11). Ribosome Protected 178 
Fragments (RPF) were isolated and the libraries were prepared following the Ingolia protocol 179 
(68).  180 
The nuclease digestion was performed on the same brain lysates used for Ribo-Seq. 181 
Two biological replicates were performed. Indexes for library preparation are listed in 182 
Supplementary Table 6. Active ribosome profiling was performed in parallel to ribosome 183 
profiling, starting from 25 µL of tissue lysates treated with RNAseI (5U/ absorbance at 260 nm).  184 
 185 
Ribosome profiling of SMN-primed ribosomes 186 
Cytoplasmic lysates from P5 brains were obtained as before (11). Endonuclease 187 
digestion was performed with RNase I (5U/Unit of absorbance at 260nm in the lysate) at rt for 188 
45 min. The reaction was stopped with SUPERase-In RNase inhibitor (Thermo Fisher 189 
Scientific). The digested lysates were centrifuged for 70 min at 100,000 rpm (TLA100.2 rotor, 190 
4°C) and the ribosome pellet solubilized in 10 mM Tris-HCl pH 7.5, 10 mM MgCl2, 150 mM 191 
NaCl, 1% Triton X-100, 600 U/mL RiboLock RNase Inhibitor (Thermo Scientific), 0.2 mg/mL 192 
cycloheximide, Protease Inhibitor Cocktail. Ribosomes associated to SMN were purified by 193 
immunoprecipitation using mouse anti-SMN antibody or anti-IgG (Abcam; Ab-18443) as a 194 
control for unspecific binding. Briefly, the ribosome suspension was incubated with 2 μL of 195 
antibody for 1 h and 40 min in orbital rotation at 4°C. Dynabeads Protein G (Life technologies) 196 
were added and incubated for 1 hr at 4°C in orbital rotation. The supernatant was removed 197 
using a magnetic stand and the beads were washed 2 times for 5 min with washing buffer (10 198 
mM Tris-HCl pH 7.5, 10 mM MgCl2, 150 mM NaCl, 1% Triton X-100, 0.2 mg/mL cycloheximide, 199 
Protease Inhibitor Cocktail) before extraction of RNA with Trizol. The ribosome protected 200 
fragments from both SMN and IgG immunoprecipitation were isolated and used for library 201 
preparation as described above. Experiments were performed in triplicate. 202 
  203 
Co-sedimentation profiles of proteins and of mRNA 204 
Polysomal profiling from cell lines or tissues as in (11). Proteins from each fraction were 205 
extracted and analysed by SDS-PAGE and western blotting as above. 206 
RNA from each sucrose fraction was extracted using TRIZOL or Phenol/chloroform as in 207 
(5). Equal volumes of RNA were used for cDNA synthesis using iScript cDNA synthesis kit. 208 
EvaGreen-based ddPCR reaction mixtures were composed of 1x QX200 EvaGreen ddPCR 209 
Supermix, 150 nM forward and reverse primers (Supplementary Table 5) and 1:10 diluted 210 
cDNA. For droplet-PCR, a 20 μL aliquot from each of the assembled ddPCR mixtures and 70 μL 211 
Droplet Generation Oil for EvaGreen were loaded into droplet generation cartridge (Bio-Rad). 212 
After sample partitioning with QX200 Droplet Generator (Bio-Rad), the entire droplet emulsion 213 
volume was transferred in a T100 thermal cycler (Bio-Rad). After PCR, droplets were read 214 
individually by QX200 Droplet Reader (Bio-Rad) and the data analysed by QuantaSoft (Bio-215 
Rad). The % of each transcript along the profile was as follows:  216 
% [mRNA copies]n= [mRNA copies]n/Σn=0->12 [mRNA copies]n 217 
where n is the number of the fraction. 218 
For qRT-PCR, the retrotranscription reaction was performed starting from the same 219 
volume of RNA obtained from each fraction (1-3 μL/polysomal profiling experiment) using the 220 
RevertAid First Strand cDNA synthesis kit (Thermo Scientific). qPCR was carried out using the 221 
CFX Connect Real-Time PCR Detection System (BioRad) using Kapa Syber Fast qPCR 222 
Mastermix (Kapa Biosystems) or qPCRBIO SyGreen Mix Separate-ROX (PCRBiosystem). 223 
Primer sequences are provided in Supplementary Table 5. The percentage of each transcript 224 
distribution along the profile was obtained using the following formula in the case qPCR:  225 
% [mRNA]n= [2^
40-Ct mRNA]n/Σn=0->12 [2^
40-Ct mRNA]n 226 
where n is the number of the fraction, %[mRNA]n is the percentage of mRNA of choice in each 227 
fraction. 228 
 229 
NMJ fluorescence microscopy 230 
For NMJ analysis, flexor digitorum brevis (FDB) muscle was dissected from early- and 231 
late-symptomatic mice using procedures similar to those described previously (69) and fixed in 232 
4% PFA for 20 min at RT. Muscles were stained for 30 minutes at RT on a rotating platform 233 
using alpha-bungarotoxin (BTX) conjugated to Alexa Fluor 594 (Invitrogen) and fasciculin-2 234 
(FCC) conjugated to Alexa Fluor 488 (Invitrogen custom production, kind gift from Prof David 235 
Beeson, University of Oxford), both at 1:1,000. FDB muscles were mounted in mowiol on 236 
microscope slides and imaged using a Nikon A1R confocal system at the IMPACT Facility, 237 
University of Edinburgh. Complete, en face neuromuscular endplates were identified based on 238 
BTX labelling (70), and BTX and FCC intensity were determined using FIJI.  239 
 240 
Data Analysis 241 
Preprocessing of ribosome profiling data. 242 
Reads were processed by removing 5ʼ adapters, discarding reads shorter than 20 243 
nucleotides and trimming the first nucleotide of the remaining ones (Trimmomatic v0.36). Reads 244 
mapping on M. musculus rRNAs (SILVA rRNA database, release 119) and tRNAs (Genomic 245 
tRNA database: gtrnadb.ucsc.edu/) were removed. Remaining reads were mapped on the 246 
mouse transcriptome (Gencode M6 transcript annotations). Antisense and duplicate reads were 247 
removed. All alignments were performed with Bowtie2 (v2.2.6) employing default settings. 248 
 249 
Identification of SMN-specific transcripts and differential analyses.  250 
Transcript counts were normalized using the trimmed mean of M-values normalization 251 
method (TMM) implemented in the edgeR Bioconductor package. Transcripts with FPKM > 1 in 252 
all the replicates of at least 1 condition were kept. Differential analyses were performed with 253 
edgeR (glmQLFTest function).  254 
SMN-specific transcripts in healthy mouse brains were selected based on 2 comparisons: 255 
1. SMN-specific RiboSeq vs IgG control, to remove any possible non-specific signal.  256 
2. SMN-specific RiboSeq vs total RiboSeq to select transcripts specifically enriched in 257 
SMN-primed ribosomes over total ribosomes. 258 
Enrichment p-values for each comparison were combined with the Fisher method and SMN-259 
specific transcripts were selected based on the following thresholds: combined p-value < 0.05, 260 
average log2 SMN-specific fold enrichment > 0.25, SMN-specific RiboSeq FPKM > 1. 261 
Genes with significant alterations in translation in SMA were selected comparing CTRL vs SMA 262 
Active-RiboSeq, with the following thresholds: absolute log2 fold change > 0.50, p-value < 0.05, 263 
Active-RiboSeq FPKM > 1. 264 
The cellular localization of the protein codified by SMN-specific transcript was downloaded from 265 
UniProt. 266 
 267 
Identification of SMN-specific communities. 268 
Protein-protein interactions between SMN-specific genes were downloaded from the 269 
STRING database (v 11.0, Mus Musculus dataset, interaction score >= 0.3). Network analysis 270 
was performed with the igraph R package (https://igraph.org/r/). SMN-specific communities 271 
within the network were identified with the cluster_fast_greedy function and ranked by gene 272 
size. The representative network shown in figure 3f was generated with the geomnet R package 273 
using the Fruchterman-Reingold Algorithm force-directed layout.  274 
 275 
Identification of brain-specific transcripts. 276 
Brain-specific transcripts were identified by merging the mRNAs selected for Active-RiboSeq 277 
and RiboSeq, using a double threshold on their signal: average FPKM and CPM values >  80th 278 
percentile. This step ensures to work with transcripts with sufficient coverage for further 279 
analysis.  280 
 281 
Positional analysis of ribosome profiling data. 282 
The identification of the P-site position within the reads was performed using riboWaltz 283 
(v1.1.0) (71) with the automatic detection of the optimal extremity and P-site offsets. For all 284 
samples of Active-RiboSeq and classical RiboSeq the optimal offset was set to 16 nucleotides 285 
from the 3’ end of the reads. For SMN-specific RiboSeq the optimal offset was set to 12 286 
nucleotides from the 5’ end of the reads. Most of the downstream analyses were performed 287 
using the following functions included in riboWaltz (71): 288 
• region_psite for the percentage of P-sites falling in the three annotated transcript regions 289 
(5' UTR, CDS and 3' UTR); 290 
• rlength_distr for the distribution of read lengths. The distribution was fitted with two 291 
Gaussian with the MASS R package; 292 
• metaprofile_psite for the metaprofiles based on the P-site position. To overlay and 293 
compare metaprofiles from different sample, the area under the curve was set to 1; 294 
• frame_psite for the percentage of P-sites falling in the three possible translation reading 295 
frames; 296 
• codon_usage_psite for the comparison between the codon usage index, based on the 297 
sum of in-frame P-sites from control and SMA. Stop codons were removed and the dots 298 
were colored according to the amino-acid frequency in the mouse transcriptome 299 
(downloaded from https://www.kazusa.or.jp/codon/). 300 
 301 
The ratios between the average number of P-sites on the first five codons (initiation) and the 302 
average number of P-sites on the whole coding sequence (CDS) was computed as follows. 303 
First, each transcript was split in two regions, including respectively the nucleotides from 0 to 14 304 
and from 15 to the end of the CDS. Second, the average number of P-site falling in the two 305 
regions and the ratio between the first and the second region was computed for each transcript. 306 
Logo-like representations of the most frequent amino-acids codified at the beginning of the CDS 307 
are based on the number of occurrences of each codon, using brain-specific transcripts 308 
previously identified as background. Triplets with fold enrichments > 1 were selected and the 309 
weighted sum among synonymous codons was computed. The resulting values are displayed 310 
as percentages. 311 
 312 
Functional enrichment analyses. 313 
Functional annotation enrichment analyses of SMN-specific transcripts, SMN-314 
communities and genes with alterations in active translation in SMA were performed with the 315 
Enrichr resource (http://amp.pharm.mssm.edu/Enrichr/) and the enrichR R package. 316 
Enrichment analysis of translational enhancer sequences was performed based on annotation 317 
retrieved from Weingarten-Gabbay et al., 2016 (50). 318 
 319 
Statistics and Reproducibility 320 
All box plots show the first quartile, median and third quartile and the whisker extends 321 
from the smallest value to the larger value at most 1.5 * IQR from the hinge. If present, notches 322 
display a confidence interval corresponding to the median +/- 1.58 * IQR/sqrt(n) where n is the 323 
number of data. 324 
Results from luciferase assays are normalized for the values in the SMN high expression 325 
cells, that were set to 1. Results are shown as the average ± SEM. Significant changes were 326 
assessed using one-sided t-test. 327 
All the other assays have been performed 2 times unless specified in the legends. For all 328 
assays, quantification and statistics were derived from n = 3 independent experiments unless 329 
specified in the legends.  330 
 331 
Data availability 332 
Ribosome profiling data generated by the current study have been deposited in the 333 
Gene Expression Omnibus (GEO) under the accession code GSE154106. Classical and active 334 
ribosome profiling data of healthy mouse brains that were reanalyzed in the current study were 335 
retrieved from GEO: GSE102318 (RiboSeq), GSE102354 (Active-RiboSeq). Source data are 336 
provided with this paper. All other data supporting the findings of this study are available from 337 
the corresponding author on reasonable request. 338 
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Rank Codon Aminoacid Distance
1 CUA Leu (L) -0.2592
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3 AGG Arg (R) -0.1324
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5 CAA Gln (Q) -0.0945
6 CGA Arg (R) 0.1266
7 GAA Glu (E) 0.1104
8 UUU Phe (F) 0.0943
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